Valuation: Glenmark Pharmaceuticals Limited

Market Cap 635B 6.66B 5.77B 5.39B 4.93B 9.28B 9.43B 63.21B 24.8B 318B 25.01B 24.47B 1,059B P/E 2026
44.2x
P/E 2027 * 27.4x
Enterprise Value 596B 6.25B 5.41B 5.06B 4.62B 8.71B 8.85B 59.3B 23.27B 298B 23.47B 22.95B 993B EV / Sales 2026
3.51x
EV / Sales 2027 * 3.7x
Free-Float
51.04%
Yield 2026
0.12%
Yield 2027 * 0.17%
1 day-1.22%
1 week+0.78%
Current month+0.78%
1 month-0.70%
3 months-4.86%
6 months+14.02%
Current year+10.62%
1 week 2,200
Extreme 2200
2,297.8
1 month 2,162
Extreme 2162
2,326.1
Current year 1,842
Extreme 1842
2,474
1 year 1,792.6
Extreme 1792.6
2,474
3 years 722.1
Extreme 722.1
2,474
5 years 348.5
Extreme 348.5
2,474
10 years 161.65
Extreme 161.65
2,474
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2000
Director of Finance/CFO 54 27/05/2025
President - 15/09/2023
Director TitleAgeSince
Director/Board Member 58 -
Chairman 56 12/05/2011
Director/Board Member 85 14/08/2009
Change 5-day change 1-year change 3-year change Capi.($)
-1.22%+0.78%+11.47%+171.70% 6.76B
-0.03%-2.32%+22.53%+68.67% 49.03B
-1.14%+13.15%+60.80%+127.29% 42.33B
+0.27%-0.37%-1.22%+15.93% 12.43B
+0.43%-0.69%+19.53%+69.15% 11.68B
-0.67%+0.39%+31.23%+141.20% 9.12B
+3.81%+7.21%+22.98%+37.90% 7.15B
+1.62%+1.47%+41.67%-12.77% 7.09B
+0.03%+8.29%-24.59%+28.71% 5.95B
+0.49%+1.18%+34.57%+100.44% 4.58B
Average +0.41%+2.29%+21.90%+74.82% 15.61B
Weighted average by Cap. -0.07%+3.58%+30.27%+83.40%

Financials

2026 2027 *
Net sales 153B 1.61B 1.39B 1.3B 1.19B 2.24B 2.27B 15.23B 5.98B 76.6B 6.03B 5.9B 255B 168B 1.76B 1.52B 1.42B 1.3B 2.45B 2.49B 16.71B 6.56B 84.01B 6.61B 6.47B 280B
Net income 20.53B 215M 186M 174M 159M 300M 305M 2.04B 802M 10.27B 808M 791M 34.21B 23.11B 242M 210M 196M 179M 338M 343M 2.3B 902M 11.56B 910M 890M 38.51B
Net Debt -39.29B -412M -357M -333M -305M -574M -583M -3.91B -1.53B -19.66B -1.55B -1.51B -65.47B -14.47B -152M -131M -123M -112M -211M -215M -1.44B -565M -7.24B -570M -557M -24.12B
Logo Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Employees
15,800
Date Price Change Volume
10/08/26 2,251.30 -1.22% 257,787
07/08/26 ₹2,279.10 +0.40% 437,610
06/08/26 ₹2,270.00 +0.49% 556,267
05/08/26 ₹2,259.00 +1.53% 388,492
04/08/26 ₹2,225.00 -0.22% 444,946
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
2,251.30INR
Average target price
2,497.73INR
Spread / Average Target
+10.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLENMARK Stock